Physician profile
Daniel J Alpert
NPI 1063412708
$10,134.26
in general payments reported to CMS, 2019-2025
28 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $627 · 2021: $852 · 2022: $1,074 · 2023: $839 · 2024: $4,482 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,478 · Debt Forgiveness: $2,970 · Education: $37.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,477.82 |
| Debt Forgiveness | $2,969.74 |
| Education | $37.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $2,969.74 | 2024 | Single Use Electrosurgical Snare Sd-400 |
| Qol Medical, LLC | $1,735.75 | 2019-2025 | Sucraid, Sucraid |
| Abbvie INC. | $866.82 | 2019-2025 | Viberzi, Linzess, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $809.60 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $498.73 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $497.71 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.19 | 2019-2024 | Trulance |
| Regeneron Healthcare Solutions, INC. | $340.68 | 2022-2024 | Dupixent |
| Celgene Corporation | $291.35 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $248.21 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $217.15 | 2019-2022 | |
| Allergan, INC. | $201.53 | 2019 | |
| Madrigal Pharmaceuticals | $195.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $177.17 | 2024-2025 | |
| Redhill Biopharma INC. | $155.63 | 2020-2024 | Talicia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $89.60 | 2021-2022 | |
| Ardelyx, INC. | $88.31 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $77.74 | 2024-2025 | Omvoh |
| Amgen INC. | $48.59 | 2025 | Uplizna |
| Ferring Pharmaceuticals INC. | $47.80 | 2022 | |
| Ironwood Pharmaceuticals, INC | $38.93 | 2021-2022 | |
| Gilead Sciences, INC. | $38.18 | 2019-2020 | |
| Shield Therapeutics INC | $19.14 | 2023 | Accrufer |
| Arbor Pharmaceuticals, INC. | $16.52 | 2019 | |
| Seqirus USA INC | $16.33 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.10 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $15.03 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Alpert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.